Ibogaine and Clonidine

Major risk. Alpha-2 agonist widely used to manage opioid withdrawal, so it is common in exactly this population. It lowers heart rate and blood pressure, and ibogaine independently causes bradycardia and hypotension — the effects are additive. Bradycardia matters twice over here: it is a hazard in its own right and it lengthens the RR interval, which is the state in which a Bazett-corrected QTc read off an ECG machine most under-reads the true value. Abrupt discontinuation causes REBOUND HYPERTENSION, which can be severe. Do NOT stop clonidine abruptly on our initiative — rebound hypertension is a real and sometimes dangerous event, and any change belongs to the prescribing physician. Expect a lower baseline heart rate, record the raw QT alongside the rate so QTc can be corrected rather than taken as printed, and monitor blood pressure through the acute phase.

Continue as prescribed — cleared by a measured lab value, not a waiting period. This medication is not stopped for treatment, and should not be stopped on our initiative — the condition it treats usually outranks the interaction. What it changes is monitoring: serum potassium and magnesium are measured before the flood dose and corrected to target, and the dose is deferred until those numbers are right rather than until a number of days have passed. Any change to the prescription belongs to the prescribing physician.

Cardiac conduction (bradycardia / AV node). Ibogaine slows the sinus node and AV conduction. Beta-blockers, non-dihydropyridine calcium channel blockers, digoxin, and lithium can deepen bradycardia or generate higher-degree AV block. Heart-rate-slowing medications are typically held on dosing day with continuous telemetry monitoring.

In many cases yes. Our medical team works with your prescribing physician to taper or substitute medications safely before treatment. The right substitution depends on the underlying condition you are treating with Clonidine — contact us for an individual review.